Lupin Opens Research Center in Florida

Indian drug maker Lupin has opened a new center for inhalation research in Coral Springs, FL. The new facility will focus on the research and development of inhalation products for the treatment of asthma, allergic rhinitis, chronic obstructive pulmonary diseases and other lung diseases.

“We are delighted to be making our mark in South Florida,” said Vinita Gupta, chief executive officer, Lupin Limited. “With the talent and resources this state provides, our Coral Springs expansion will further strengthen our ability to bring quality, affordable pharmaceuticals to patients in the U.S. and other key markets globally. The new inhalation research and development facility is a significant step forward in our journey to emerge as a global specialty pharmaceutical player.”

Headquartered in Mumbai, Lupin produces and develops a wide range of branded and generic formulations, APIs and biotechnology products. The company is a significant player in the cardiovascular, diabetology, asthma, pediatric, CNS, GI, anti-infective and NSAID space and holds global leadership positions in the anti-TB and cephalosporin segment.

According to IMS Health, Lupin is the 5th largest and fastest growing generics player in the U.S. with a 5.3% market share by prescriptions, and the 3rd largest Indian pharmaceutical company by sales. IMS data also says Lupin is the fastest growing top 10 generic pharmaceutical player in Japan and South Africa.

For the financial year ended March 31, 2015, Lupin’s consolidated turnover and profit after tax were $2.06 billion and $393 million) respectively.